Alkem Laboratories Ltd (ALKEM) is currently trading at 5,397.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Alkem Laboratories Limited is a Mumbai-headquartered integrated pharmaceutical company that develops, manufactures and sells branded generics, generic formulations, APIs, biosimilars and nutraceuticals in India and internationally, supported by 18 manufacturing facilities, R&D centres and a growing subsidiary ecosystem (Enzene, Alkem MedTech, Ascend, Pharmacor and others). Q3 FY26 results showed resilient performance: consolidated revenue of ₹37,368 million (+10.7% YoY), EBITDA ₹8,280 million at a 22.2% margin and PAT of ₹6,360 million, while international businesses grew 26.6% YoY led by the US and non‑US markets, signalling successful portfolio and geographic execution. Strategic expansion into MedTech was announced via a binding term sheet to acquire majority stake in Occlutech, giving Alkem immediate presence in minimally invasive cardiac implants and a high‑value device pipeline, with management projecting Alkem MedTech to become a meaningful growth and margin contributor over the next 3–5 years. R&D and pipeline depth are notable: Alkem disclosed 188 ANDA filings and 167 approvals (including tentative), ongoing NDAs/BLAs, Q3 R&D spend of ₹1,390 million (3.7% of sales) and planned GLP‑1 semaglutide domestic launch in March 2026, highlighting biologics and specialty chronic therapies as focus areas. Balance sheet strength and regulatory progress underpin optionality: net cash of ₹55.9 billion as of Dec 31, 2025, multiple facilities with recent EIRs or clean inspection outcomes, and an active ANDA approval cadence that supports US growth and cross‑border expansion.

Over the past 52 weeks, Alkem Laboratories Ltd has traded between a low of ₹5,085.00 and a high of ₹5,933.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Alkem Laboratories Ltd has a market capitalization of approximately 64,535.21. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Alkem Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 29.91 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 64,535.21 Cr, Alkem Laboratories Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Alkem Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Alkem Laboratories Ltd is 29.91. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Alkem Laboratories’ 52nd AGM is scheduled for Thursday, 27 August 2026 at 11:00 AM IST, to be held via VC/OAVM.

Revenue from operations rose 11% YoY to ₹3,740 crore, while consolidated net profit fell to ₹520 crore from ₹664 crore in Q1 FY26.

The board approved the standalone and consolidated unaudited financial results at its meeting held on August 14, 2026.

Revenue from operations rose to about ₹3,740 crore, while consolidated net profit was reported at ₹520 crore versus ₹664 crore a year earlier.